| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6156876 | American Journal of Kidney Diseases | 2015 | 6 Pages |
Abstract
Few trials directly comparing DPO and EPO have been conducted and follow-up was limited. In aggregate, no effect of specific erythropoiesis-stimulating agent on mortality was identified, but the confidence limits were wide and remained compatible with considerable harm from DPO. Absent adequately powered randomized trials, observational postmarketing comparative effectiveness studies comparing these erythropoiesis-stimulating agents are required to better characterize the long-term safety profiles of these agents.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Emilee R. MD, MSc, Wolfgang C. MD, ScD, MPH,